Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2023 and 2024.
-
Tight liquidity NBB
Cash and receivables cover 43 % of short-term debt in 2024; threshold 65 %.
Financials
Financial year 2024
Bellipharma from Schaarbeek, company number BE0844039461, closed financial year 2024 with a result of € -19,063 after tax. For that financial year Bellipharma recorded a gross margin of € 28,379 and equity of € 223,865. Compared with financial year 2023, the result moved from € -18,720 to € -19,063. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on December 17, 2025.
€ 223,865
▼ 8% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -19,063
▼ 2 % more loss than in 2023
Profit after tax over the fiscal year.
€ 44,182
▲ 36% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 43,265.
People and assets in 2024
€ 23,651
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 17,308
▼ 40% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 2,727
▼ 79% vs 2023
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Revenue | - | € 637,289 | - | - | |
| Gross margin | € 144,795 | € 80,364 | € 5,821 | € 28,379 | ▲ € 22,558 |
| Profit after taxes | € 99,286 | € 24,650 | € -18,720 | € -19,063 | ▼ € 343 |
| Equity | € 236,997 | € 261,648 | € 242,928 | € 223,865 | ▼ 8% |
| Total debts | € 233,608 | € 237,378 | € 158,365 | € 224,421 | ▲ 42% |
| Cash | € 10,618 | € 5,902 | € 32,569 | € 44,182 | ▲ 36% |
| Retained profit | € 56,397 | € 81,048 | € 62,328 | € 43,265 | ▼ 31% |
| Bank debt | € 205,241 | € 155,208 | € 114,344 | € 0 | ▼ 100% |
| Balance sheet total | € 470,606 | € 499,026 | € 401,293 | € 448,286 | ▲ 12% |
Key figures of Bellipharma, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to Bellipharma?
What happened at Bellipharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 19,063. filed late Source: NBB ↗
- Start of the company according to the CBE. KBO
- New establishment in Schaarbeek. KBO
In short
From € 99,286 profit in 2021 to € 19,063 loss in 2024.
Paid € 24,843 in corporate taxes since 2021.
Best year ever: 2021, with € 99,286 profit.
A new publication or filing at Bellipharma? We notify you, reason included.
Follow BellipharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Crown Consultancy comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
BellipharmaBehind Bellipharma is NOVESTA BV. The shares are held by Crown Consultancy (100%).
Directors
According to the 2024 annual accounts
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Simon Bolivarlaan 21-23
1030 Schaarbeek
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
OVH Mail
Hosting
INFOMANIAK-AS, CH
Website info
Features
Security
Network
Details
- Company number
- 0844.039.461
- VAT number
- BE 0844.039.461
- Registered office
- Simon Bolivarlaan 21-23, 1030 Schaarbeek
- Names & denominations
- Bellipharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 February 2012
- Peppol
- Active · Active since 30 Jan 2025
- Activities · NACE
Detailhandel in farmaceutische producten